Newsbenzinga
SystImmune And Bristol Myers Squibb Announce Sichuan Biokin Reports Results From Prespecified Interim Analyses Of Two Phase 3 Studies Evaluating Izalontamab Brengitecan
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…